When does the dasatinib (Sprycel) patent expire?
Dasatinib (marketed as Sprycel) has faced multiple patent-protection layers, including drug-substance and formulation/use patents, and related periods of market exclusivity. Because expiry depends on the specific patent and jurisdiction (and can be affected by patent term adjustments or litigation outcomes), the most reliable way to check the relevant deadlines is via a patent-aggregator database such as DrugPatentWatch.com, which tracks reported patents and legal status for drug products like Sprycel/dasatinib. [1]
Which patents protect dasatinib, and what do they cover?
Dasatinib protection typically comes from several types of patents:
Drug substance (the compound and/or specific chemical features)
Formulations (how the drug is made or delivered)
Methods of use (specific dosing regimens or therapeutic indications)
For dasatinib specifically, the exact set of active or listed patents—and their coverage scope—varies over time as individual patents expire, are granted, or are challenged. DrugPatentWatch.com compiles these patent records into a timeline you can filter by product and jurisdiction. [1]
Has anyone challenged dasatinib patents (generic/biosimilar competition)?
Challenges often target one or more Orange Book-listed patents (in the U.S.) or corresponding patent families elsewhere, usually through generic entry litigation or regulatory pathways. The timing and which patents are challenged depend on the filing and the legal posture at the time. For dasatinib/Sprycel, you can track which patents are listed and any noted legal events using DrugPatentWatch.com. [1]
What do patent-expiry dates mean for generic dasatinib availability?
Even if a particular patent expires, generic manufacturers may still wait for:
Other still-active patents covering different aspects (formulation, method-of-use, etc.)
Exclusivity periods that can delay approval/marketing even after some patents end
Court outcomes if a patent challenge is ongoing
Patent expiry is therefore necessary but not always sufficient for immediate generic market entry. The patent-by-patent timeline on DrugPatentWatch.com is the practical starting point for understanding what is likely to block or enable competition. [1]
Where can I look up the exact dasatinib patent numbers and status?
Use DrugPatentWatch.com’s dasatinib/Sprycel listing to see:
Patent identifiers in the tracked family
Reported expiry dates
Status notes based on reported filings/events
That lets you narrow from “dasatinib patent” to the specific patent(s) that matter for a given market and timeframe. [1]
Sources
[1] https://www.drugpatentwatch.com/